This phase II trial will combine two types of chemotherapy (venetoclax and cytarabine) for the treatment of acute myeloid leukaemia that has not responded or gotten worse with prior therapies.
This trial is treating patients with Acute Myeloid Leukaemia.
This is a systemic therapy trial.
You may be able to join this trial if:
- You have had treatment but your cancer has gotten worse or has not responded to the treatment you have been given.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
- You have been diagnosed with a prior or secondary type of cancer.
- You have had certain treatments, surgical procedures or drugs.
- You have previously been treated (or are currently being treated) on a clinical trial.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Use the hyperlinks, where available to access additional clinical trial information.
A phase 2 study of venetoclax in combination with low-dose cytarabine in relapsing acute myeloid leukemia
Other Non-Commercial Sponsor
All eligible patients will receive 600mg of oral venetoclax once daily (QD) in a 28-day cycle. This will be followed, on Days 1-10 of every cycle, by a subcutaneous injection of cytarabine (20mg/m2) once daily. Patients will remain on treatment for up to 24 cycles unless discontinuation criteria is met.
Recruiting Hospitals Read More
Not Recruiting Hospitals Read More